{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:38:28Z","timestamp":1775597908729,"version":"3.50.1"},"reference-count":81,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Helicobacter pylori (H. pylori) infection is a significant global health concern, affecting approximately 50% of the world\u2019s population and leading to gastric ulcers, gastritis, and gastric cancer. The increase in antibiotic resistance has compromised the efficacy of existing therapeutic regimens, necessitating novel approaches for effective eradication. This study aimed to develop a targeted liposomal drug delivery system incorporating furazolidone and N-acetylcysteine (NAC) to enhance mucopenetration and improve Helicobacter pylori eradication. Liposomes were formulated with furazolidone, NAC, and Pluronic F-127 using a modified reverse-phase evaporation technique. The formulations were categorized based on charge as neutral, negative, and positive and tested for mucopenetration using a modified silicon tube method with coumarin-6 as a fluorescent marker. The encapsulation efficiency and particle size were analyzed using HPLC and an Izon q-nano particle size analyzer. The results indicated that charged liposomes showed a higher encapsulation efficiency than neutral liposomes with Pluronic F-127. Notably, combining furazolidone with 1% NAC achieved complete eradication of H. pylori in 2.5 h, compared to six hours without NAC. The findings of this study suggest that incorporating NAC and Pluronic F-127 into liposomal formulations significantly enhances mucopenetration and antimicrobial efficacy.<\/jats:p>","DOI":"10.3390\/pharmaceutics16091123","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T03:14:31Z","timestamp":1724642071000},"page":"1123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Muhammad Irfan","family":"Alam","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Paget","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla Yussuf","family":"Moosa","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husein","family":"Alghurairy","sequence":"additional","affiliation":[{"name":"Dudley Group NHS Foundation Trust, Dudley DY1 2HQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0781-1127","authenticated-orcid":false,"given":"Amal Ali","family":"Elkordy","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"\u00d6ztekin, M., Y\u0131lmaz, B., A\u011fag\u00fcnd\u00fcz, D., and Capasso, R. (2021). Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases, 9.","DOI":"10.3390\/diseases9040066"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ali, A., and AlHussaini, K.I. (2024). Helicobacter pylori: A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. Microorganisms, 12.","DOI":"10.3390\/microorganisms12010222"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3748\/wjg.v26.i10.995","article-title":"Global whole family based-Helicobacter pylori eradication strategy to prevent its related diseases and gastric cancer","volume":"26","author":"Ding","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-1302-3_1","article-title":"An overview of Helicobacter pylori infection","volume":"Volume 2283","author":"Smith","year":"2021","journal-title":"Helicobacter pylori"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Elbehiry, A., Marzouk, E., Aldubaib, M., Abalkhail, A., Anagreyyah, S., Anajirih, N., Almuzaini, A.M., Rawway, M., Alfadhel, A., and Draz, A. (2023). Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020191"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5694\/mja16.00104","article-title":"Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection","volume":"10","author":"Mitchell","year":"2016","journal-title":"Med. J. Aust."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/19490976.2017.1421887","article-title":"When is Helicobacter pylori acquired in populations in developing countries? A birth-cohort study in Bangladeshi children","volume":"9","author":"Kienesberger","year":"2018","journal-title":"Gut Microbes"},{"key":"ref_8","unstructured":"Guts Charity (2024, July 17). Helicobacter\u00a0pylori. Available online: https:\/\/gutscharity.org.uk\/advice-and-information\/conditions\/helicobacter-pylori\/."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Roberts, L.T., Issa, P.P., Sinnathamby, E.S., Granier, M., Mayeux, H., Eubanks, T.N., Malone, K., Ahmadzadeh, S., Cornett, E.M., and Shekoohi, S. (2022). Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice. Life, 12.","DOI":"10.3390\/life12122038"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","article-title":"Helicobacter pylori infection and antibiotic resistance\u2014From biology to clinical implications","volume":"18","author":"Yamaoka","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejps.2016.01.017","article-title":"Formulation and advantages of furazolidone in liposomal drug delivery systems","volume":"84","author":"Alam","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Resina, E., and Gisbert, J.P. (2021). Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant, H. pylori infection. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091028"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5539\/gjhs.v7n1p235","article-title":"Low dose furazolidone for eradication of Helicobacter pylori instead of clarithromycin: A clinical trial","volume":"7","author":"Hajaghamohammadi","year":"2014","journal-title":"Glob. J. Health Sci."},{"key":"ref_14","unstructured":"Jorgensen, J.H., Carroll, K.C., Funke, G., Pfaller, M.A., Landry, M.L., Richter, S.S., and Warnock, D.W. (2015). Mechanisms of resistance to antiparasitic agents. Antibiotic and Chemotherapy: Anti-Infective Agents and Their Mechanisms of Action, ASM Press."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e037375","DOI":"10.1136\/bmjopen-2020-037375","article-title":"Safety of furazolidone-containing regimen in Helicobacter pylori infection: A systematic review and meta-analysis","volume":"10","author":"Ji","year":"2020","journal-title":"BMJ Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1753465812437563","article-title":"N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease","volume":"6","author":"Sadowska","year":"2012","journal-title":"Therap. Adv. Respir. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kalyanaraman, B. (2022). NAC, NAC, Knockin\u2019 on Heaven\u2019s door: Interpreting the mechanism of action of N-acetylcysteine in tumor and immune cells. Redox Biol., 57.","DOI":"10.1016\/j.redox.2022.102497"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40248-016-0039-2","article-title":"N-acetylcysteine in COPD: Why, how, and when?","volume":"11","author":"Sanguinetti","year":"2016","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejps.2014.09.017","article-title":"Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: Development, in vitro characterization and antioxidant activity","volume":"65","author":"Ourique","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kundukad, B., Schussman, M., Yang, K., Seviour, T., Yang, L., Rice, S.A., Kjelleberg, S., and Doyle, P.S. (2017). Mechanistic action of weak acid drugs on biofilms. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-05178-3"},{"key":"ref_21","first-page":"107","article-title":"Effect of oral N-acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia","volume":"59","author":"Karbasi","year":"2013","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_22","first-page":"CD012357","article-title":"N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication","volume":"2","author":"Fontes","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","first-page":"247","article-title":"N-Acetylcysteine for Gastric Lactobezoars in a 1-Month-Old","volume":"24","author":"Savva","year":"2019","journal-title":"J. Pediatr. Pharmacol. Therap."},{"key":"ref_24","unstructured":"Banerjee, S., and McCormack, S. (2019). Acetylcysteine for Patients Requiring Mucous Secretion Clearance: A Review of Clinical Effectiveness and Safety [Internet], Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"540271","DOI":"10.1155\/2015\/540271","article-title":"An additive effect of oral N-acetyl cysteine on eradication of Helicobacter pylori","volume":"2015","author":"Hamidian","year":"2015","journal-title":"J. Pathog."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/bp0342553","article-title":"Transport of polymeric nanoparticle gene carriers in gastric mucus","volume":"20","author":"Dawson","year":"2004","journal-title":"Biotechnol. Prog."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nmat2347","article-title":"Drug delivery: Stealth particles give mucus the slip","volume":"8","author":"Yen","year":"2009","journal-title":"Nat. Mater."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Khaliq, N.U., Lee, J., Kim, S., Sung, D., and Kim, H. (2023). Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082102"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.actbio.2020.04.028","article-title":"Poloxamer: A versatile tri-block copolymer for biomedical applications","volume":"110","author":"Zarrintaj","year":"2020","journal-title":"Acta Biomater."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11010-022-04481-6","article-title":"Pluronic F127-liposome-encapsulated curcumin activates Nrf2\/Keap1 signaling pathway to promote cell migration of HaCaT cells","volume":"478","author":"Zhou","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Su, S., and M Kang, P. (2020). Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090837"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Couce, J., Tom\u00e1s, M., Fuentes, G., Que, I., Almirall, A., and Cruz, L.J. (2022). Chitosan\/Pluronic F127 Thermosensitive Hydrogel as an Injectable Dexamethasone Delivery Carrier. Gels, 8.","DOI":"10.3390\/gels8010044"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.18433\/J3HW2B","article-title":"Pluronic\u00ae F-127 and Pluronic Lecithin Organogel (PLO): Main features and their applications in topical and transdermal administration of drugs","volume":"15","author":"Almeida","year":"2012","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1166\/jbn.2014.1788","article-title":"The modulation of the permeability and the cellular uptake of liposome by stable anchoring of lipid-conjugated pluronic on liposome","volume":"10","author":"Kim","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.gt.3301525","article-title":"Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium","volume":"8","author":"Ferrari","year":"2001","journal-title":"Gene Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e09394","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: Structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1021\/la402695c","article-title":"Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery","volume":"29","author":"Thamphiwatana","year":"2013","journal-title":"Langmuir ACS J. Surf. Colloids"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/02652048.2016.1202343","article-title":"Preparation and optimisation of anionic liposomes for delivery of small peptides and cDNA to human corneal epithelial cells","volume":"33","author":"Neves","year":"2016","journal-title":"J. Microencapsul."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12668-022-00941-x","article-title":"A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents","volume":"12","author":"Andra","year":"2022","journal-title":"BioNanoScience"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"122616","DOI":"10.1016\/j.lfs.2024.122616","article-title":"Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions","volume":"346","author":"Paramshetti","year":"2024","journal-title":"Life Sci."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sercombe, L., Veerati, T., Moheimani, F., Wu, S.Y., Sood, A.K., and Hua, S. (2015). Advances and Challenges of Liposome Assisted Drug Delivery. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00286"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Inglut, C.T., Sorrin, A.J., Kuruppu, T., Vig, S., Cicalo, J., Ahmad, H., and Huang, H.C. (2020). Immunological and Toxicological Considerations for the Design of Liposomes. Nanomaterials, 10.","DOI":"10.3390\/nano10020190"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liu, P., Chen, G., and Zhang, J. (2022). A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules, 27.","DOI":"10.3390\/molecules27041372"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","volume":"532","author":"Leal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1021\/acsbiomaterials.2c00047","article-title":"Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier","volume":"8","author":"Watchorn","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.copbio.2018.03.010","article-title":"Selective permeability of mucus barriers","volume":"52","author":"Witten","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Nogueira","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cheng, H.M., Mah, K.K., and Seluakumaran, K. (2020). Gastric mucosal barrier, Helicobacter pylori. Defining Physiology: Principles, Themes, Concepts, Springer.","DOI":"10.1007\/978-3-030-62285-5"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0005-2736(93)90398-J","article-title":"Characterization of 5-fluorouracil loaded liposomes prepared by reverse-phase evaporation or freezing-thawing extrusion methods: Study of drug release","volume":"1153","author":"Elorza","year":"1993","journal-title":"Biochim. Biophys. Acta (BBA) Biomembr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/026520499289220","article-title":"Preparation of liposomes by reverse-phase evaporation using alternative organic solvents","volume":"16","author":"Cortesi","year":"1999","journal-title":"J. Microencapsul."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1086\/497881","article-title":"Thermal SiO and H13CO+ line observations of the dense molecular cloud G0.11-0.11 in the Galactic Center Region","volume":"636","author":"Handa","year":"2006","journal-title":"Astrophys. J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Liu, D., Li, J., Pan, H., He, F., Liu, Z., Wu, Q., Bai, C., Yu, S., and Yang, X. (2016). Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. Sci. Rep., 6.","DOI":"10.1038\/srep28796"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Homayun, B., Lin, X., and Choi, H.J. (2019). Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11030129"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajps.2014.12.007","article-title":"Developments of mucus penetrating nanoparticles","volume":"10","author":"Liu","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_56","first-page":"173","article-title":"Pharmaceutical nanoparticles and the mucin biopolymer barrier","volume":"2","author":"Aljayyoussi","year":"2012","journal-title":"BioImpacts"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1021\/bm501419z","article-title":"Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus","volume":"15","author":"Ensign","year":"2014","journal-title":"Biomacromolecules"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0006-3495(01)75844-4","article-title":"Diffusion of macromolecules and virus-like particles in human cervical mucus","volume":"81","author":"Olmsted","year":"2001","journal-title":"Biophys. J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Guo, S., Liang, Y., Liu, L., Yin, M., Wang, A., Sun, K., Li, Y., and Shi, Y. (2019). Research on the fate of polymeric nanoparticles in the process of intestinal absorption based on model nanoparticles with various characteristics: Size, surface charge and pro-hydrophobics. J. Nanobiotechnol., 19.","DOI":"10.1186\/s12951-021-00770-2"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/anie.201006849","article-title":"Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus","volume":"50","author":"Yang","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.addr.2017.12.006","article-title":"Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems","volume":"124","author":"Chater","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","article-title":"Mucolytics in cystic fibrosis","volume":"8","author":"Henke","year":"2007","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ten\u00f3rio, M.C.D.S., Graciliano, N.G., Moura, F.A., Oliveira, A.C.M., and Goulart, M.O.F. (2021). N-Acetylcysteine (NAC): Impacts on human health. Antioxidants, 10.","DOI":"10.3390\/antiox10060967"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1021\/bm0493990","article-title":"Viscoelastic properties and dynamics of porcine gastric mucin","volume":"6","author":"Celli","year":"2005","journal-title":"Biomacromolecules"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cll.2014.08.008","article-title":"The impact of proton pump inhibitors on the human gastrointestinal microbiome","volume":"34","author":"Freedberg","year":"2014","journal-title":"Clin. Lab. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1021\/bm0505843","article-title":"Atomic force microscopy reveals aggregation of gastric mucin at low pH","volume":"6","author":"Hong","year":"2005","journal-title":"Biomacromolecules"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1802057","DOI":"10.1183\/13993003.02057-2018","article-title":"Dropping acid: Why is cystic fibrosis mucus abnormal?","volume":"52","author":"Rubin","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/nnm.10.123","article-title":"Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine","volume":"6","author":"Jung","year":"2011","journal-title":"Nanomedicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/mt.2016.182","article-title":"The mucus barrier to inhaled gene therapy","volume":"24","author":"Duncan","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_70","first-page":"311","article-title":"In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels","volume":"56","author":"Mohamed","year":"2006","journal-title":"Acta Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jsps.2010.07.003","article-title":"Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes","volume":"18","author":"Yahiya","year":"2010","journal-title":"Saudi Pharm. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.7150\/thno.4949","article-title":"Cholesterol derivatives based charged liposomes for doxorubicin delivery: Preparation, in vitro and in vivo characterization","volume":"2","author":"Yu","year":"2012","journal-title":"Theranostics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijantimicag.2005.10.021","article-title":"Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: A time-kill study","volume":"27","author":"Rukholm","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhao, T., and Liu, Y. (2010). N-acetylcysteine inhibits biofilms produced by Pseudomonas aeruginosa. BMC Microbiol., 10.","DOI":"10.1186\/1471-2180-10-140"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1128\/AAC.00710-10","article-title":"N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility","volume":"54","author":"Goswami","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/MCG.0b013e31822be4d6","article-title":"The potential role of N-acetylcysteine for the treatment of Helicobacter pylori","volume":"45","author":"Kian","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"101832","DOI":"10.1016\/j.clinre.2021.101832","article-title":"The efficacy of adjuvant N-acetyl cysteine for the eradication of H. pylori infections: A systematic review and meta-analysis of randomized clinical trials","volume":"46","author":"Biswas","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1128\/AAC.48.10.3782-3788.2004","article-title":"Effect of glycine on Helicobacter pylori in vitro","volume":"48","author":"Masaaki","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","unstructured":"Parisa, J., Mohsen, A., Abbas, Y., Rasool, N., and Roghayeh, T. (2023). Evaluation inhibitory effect of glycine on Helicobacter pylori in experimental condition. Res. Sq., advance online publication."},{"key":"ref_81","first-page":"9","article-title":"Gastro-retentive floating drug delivery system\u2014An approach in gastroretentive drug delivery","volume":"3","author":"Rajak","year":"2011","journal-title":"Int. J. Pharm. Sci."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:42:42Z","timestamp":1760110962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":81,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["pharmaceutics16091123"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16091123","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}